Caxton Associates LLP Sells 1,986 Shares of Labcorp Holdings Inc. $LH

Caxton Associates LLP lowered its holdings in shares of Labcorp Holdings Inc. (NYSE:LH) by 29.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,845 shares of the medical research company’s stock after selling 1,986 shares during the quarter. Caxton Associates LLP’s holdings in Labcorp were worth $1,293,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in Labcorp in the fourth quarter worth $26,000. Hilton Head Capital Partners LLC bought a new stake in shares of Labcorp during the fourth quarter worth $27,000. JPL Wealth Management LLC purchased a new stake in shares of Labcorp during the third quarter valued at $28,000. Eagle Bay Advisors LLC purchased a new stake in shares of Labcorp during the fourth quarter valued at $29,000. Finally, DV Equities LLC bought a new position in shares of Labcorp in the fourth quarter worth about $29,000. Institutional investors own 95.94% of the company’s stock.

Labcorp Price Performance

Shares of LH stock opened at $296.71 on Friday. Labcorp Holdings Inc. has a twelve month low of $244.52 and a twelve month high of $298.58. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. The stock has a fifty day simple moving average of $269.38 and a two-hundred day simple moving average of $269.09. The stock has a market capitalization of $24.33 billion, a price-to-earnings ratio of 26.28, a P/E/G ratio of 1.97 and a beta of 0.89.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, beating the consensus estimate of $4.09 by $0.16. The firm had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The business’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm posted $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, analysts predict that Labcorp Holdings Inc. will post 18 EPS for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.0%. The ex-dividend date is Friday, August 28th. Labcorp’s dividend payout ratio is presently 25.51%.

Wall Street Analyst Weigh In

Several research analysts recently commented on LH shares. Robert W. Baird raised their price target on shares of Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Evercore reissued an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a research report on Wednesday, April 8th. Weiss Ratings upgraded shares of Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Bank of America lifted their price target on shares of Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Eight research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $315.33.

Insider Buying and Selling at Labcorp

In other news, EVP Bryan T. Vaughn sold 234 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the completion of the sale, the executive vice president owned 6,746 shares of the company’s stock, valued at approximately $1,930,637.74. This represents a 3.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Kathryn W. Kyle sold 762 shares of the stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $263.89, for a total transaction of $201,084.18. Following the transaction, the executive vice president owned 3,813 shares in the company, valued at approximately $1,006,212.57. This represents a 16.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 6,991 shares of company stock valued at $1,796,696. Company insiders own 0.84% of the company’s stock.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.